Notice of Dividend Amount • Apr 3, 2020
Notice of Dividend Amount
Open in ViewerOpens in native device viewer
Medistim ASA: Change of dividend proposal for the financial years 2019
Oslo, 3rd of April 2020) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the board of directors of Medistim ASA has in an extraordinary board meeting today, decided to change their dividend proposal for the financial year 2019.
Reference is made to the stock exchange announcement by Medistim on 28 February 2020 regarding the board of directors’ proposed dividend of NOK 2.75 per share for the financial year 2019, and the stock exchange announcement dated 19 March 2020 addressing the implications of the Covid-19 virus on Medistim's operations.
Due to the ongoing Covid-19 situation and the general uncertainties resulting therefrom, the board of directors has decided to change its dividend proposal for the financial year 2019 from a fixed dividend to an authorization to the board of directors to resolve a dividend based on the financial statements for the financial year 2019. The proposed authorization will be limited to NOK 2.75 per share, equal to the initially proposed dividend, with a term until the annual general meeting in 2021.
Although the Covid-19 virus has not yet had any significant negative implications on Medistim and its operations, it is, as indicated in the stock exchange announcement on 19 March 2020, too early to assess the long-term effects of the virus on Medistim with certainty. It is anticipated that hospitals will postpone some elective surgeries, which could negatively impact sales of consumables. Some hospitals are also implementing access restrictions, that may lead to delays in new sales projects. Given this uncertainty, the board of directors is of the opinion that it is prudent, and in the best interest of the company and its shareholders, to await further developments before potentially deciding to resolve a dividend for the financial year 2019.
The proposed dividend authorization will be placed on the agenda for Medistim's annual general meeting to be held on 28 April 2020. Except for the above-mentioned amended dividend proposal, there are no changes to Medistim's financial figures for 2019 published on 19 March 2020.
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.